{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:10:02Z","timestamp":1791943802165,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00259-025-07556-w","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T03:34:27Z","timestamp":1759116867000},"page":"1822-1835","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bone matters: Ga-68 PSMA PET\/CT volumetrics predict PSA-PFS and OS in bone-dominant mCRPC patients treated with [\u00b9\u2077\u2077Lu]Lu-PSMA-617"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6440-4219","authenticated-orcid":false,"given":"Mehmet O\u011fuz","family":"Kartal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1745-6672","authenticated-orcid":false,"given":"Ay\u015fenur Sinem","family":"Kartal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naz\u0131m","family":"Co\u015fkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali Nahit","family":"\u015eendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"7556_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, De Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"7556_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825\u201333.","journal-title":"Lancet Oncol"},{"key":"7556_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"7556_CR4","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.2967\/jnumed.120.260836","volume":"62","author":"K Michalski","year":"2021","unstructured":"Michalski K, Klein C, Br\u00fcggemann T, Meyer PT, Jilg CA, Ruf J. Assessing response to177 Lu-PSMA radioligand therapy using modified PSMA PET progression criteria. J Nucl Med. 2021;62:1741\u20136.","journal-title":"J Nucl Med"},{"key":"7556_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/j.semnuclmed.2023.06.003","volume":"54","author":"PE Hartrampf","year":"2024","unstructured":"Hartrampf PE, Serfling SE, Michalski K, Buck AK, Werner RA. PSMA PET\/CT for response assessment of 177Lu-PSMA therapy. Semin Nucl Med. 2024;54:69\u201376.","journal-title":"Semin Nucl Med"},{"key":"7556_CR6","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","volume":"49","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Fendler WP, Murthy V, Hui W, Armstrong WR, et al. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022;49:4271\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7556_CR7","doi-asserted-by":"publisher","unstructured":"Karpinski MJ, Rahbar K, B\u00f6gemann M, et al. Updated prostate cancer risk groups by prostate-specific membrane antigen positron emission tomography prostate cancer molecular imaging standardized evaluation (PPP2): results from an international multicentre registry study. Eur Urol. 2025;20(25):0302\u20132838. https:\/\/doi.org\/10.1016\/j.eururo.2025.04.017.","DOI":"10.1016\/j.eururo.2025.04.017"},{"key":"7556_CR8","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, et al. Quantitative68 Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following177 Lu-PSMA-617 (VISION trial). Radiology. 2024;312:e233460.","journal-title":"Radiology"},{"key":"7556_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2020.05.004","volume":"78","author":"A Gafita","year":"2020","unstructured":"Gafita A, Fendler WP, Hui W, Sandhu S, Weber M, Esfandiari R, et al. Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study. Eur Urol. 2020;78:148\u201354.","journal-title":"Eur Urol"},{"key":"7556_CR10","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.18632\/oncotarget.26789","volume":"10","author":"FE von Eyben","year":"2019","unstructured":"von Eyben FE, Singh A, Zhang J, Nipsch K, Meyrick D, Lenzo N, et al. 177 Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer. Oncotarget. 2019;10:2451\u201361.","journal-title":"Oncotarget"},{"key":"7556_CR11","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7556_CR12","doi-asserted-by":"publisher","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","volume":"78","author":"C Nioche","year":"2018","unstructured":"Nioche C, Orlhac F, Boughdad S, Reuz\u00e9 S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res. 2018;78:4786\u20139.","journal-title":"Cancer Res"},{"key":"7556_CR13","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","volume":"47","author":"J Ferdinandus","year":"2020","unstructured":"Ferdinandus J, Violet J, Sandhu S, Hicks RJ, Ravi Kumar AS, Iravani A, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020;47:2322\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7556_CR14","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00259-023-06476-x","volume":"51","author":"C Burgard","year":"2024","unstructured":"Burgard C, Hein C, Blickle A, Bartholom\u00e4 M, Maus S, Petto S, et al. Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry. Eur J Nucl Med Mol Imaging. 2024;51:885\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7556_CR15","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222148","volume":"308","author":"A Gafita","year":"2023","unstructured":"Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, et al. Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer. Radiology. 2023;308:e222148.","journal-title":"Radiology"},{"key":"7556_CR16","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. JCO. 2016;34:1402\u201318.","journal-title":"JCO"},{"key":"7556_CR17","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","volume":"50","author":"PE Hartrampf","year":"2023","unstructured":"Hartrampf PE, H\u00fcttmann T, Seitz AK, K\u00fcbler H, Serfling SE, Schl\u00f6telburg W, et al. SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T. Eur J Nucl Med Mol Imaging. 2023;50:3465\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7556_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60:517\u201323.","journal-title":"J Nucl Med"},{"key":"7556_CR19","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.3390\/cancers13153715","volume":"13","author":"K Seifert","year":"2021","unstructured":"Seifert K, Seifert R, Kessel K, Roll W, Schlack K, Boegemann M, et al. Lutetium-177 labelled PSMA targeted therapy in advanced prostate cancer: current status and future perspectives. Cancers. 2021;13:3715.","journal-title":"Cancers"},{"key":"7556_CR20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2967\/jnumed.123.267014","volume":"65","author":"M Swiha","year":"2024","unstructured":"Swiha M, Papa N, Sabahi Z, Ayati N, John N, Pathmanandavel S, et al. Development of a visually calculated SUVmean (HIT score) on screening PSMA PET\/CT to predict treatment response to177 Lu-PSMA therapy: comparison with quantitative SUVmean and patient outcomes. J Nucl Med. 2024;65:904\u20138.","journal-title":"J Nucl Med"},{"key":"7556_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/ERC-18-0226","volume":"26","author":"MK Bakht","year":"2019","unstructured":"Bakht MK, Derecichei I, Li Y, Ferraiuolo R-M, Dunning M, Oh SW, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocrine-related Cancer. 2019;26:131\u201346.","journal-title":"Endocrine-related Cancer"},{"key":"7556_CR22","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00259-025-07078-5","volume":"52","author":"PMA Waibel","year":"2025","unstructured":"Waibel PMA, Glavynskyi I, Fechter T, Mix M, Kind F, Sigle A, et al. Can PSMA PET detect intratumour heterogeneity in histological PSMA expression of primary prostate cancer? Analysis of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007. Eur J Nucl Med Mol Imaging. 2025;52:2023\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7556_CR23","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23:1389\u201397.","journal-title":"Lancet Oncol"},{"key":"7556_CR24","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1007\/s00259-025-07198-y","volume":"52","author":"T Telli","year":"2025","unstructured":"Telli T, Lopes L, Karpinski M, Pabst KM, Gr\u00fcnwald V, Shi K, et al. Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC. Eur J Nucl Med Mol Imaging. 2025;52:3199\u2013210.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7556_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen Y-H, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"7556_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2967\/jnumed.124.268441","volume":"66","author":"LM Unterrainer","year":"2025","unstructured":"Unterrainer LM, Hope TA, Fendler WP, Grogan T, Ndlovu H, Armstrong W, et al. Low- and high-volume disease in metastatic hormone-sensitive prostate cancer: from CHAARTED to PSMA PET\u2014an international multicenter retrospective study. J Nucl Med. 2025;66:54\u201360.","journal-title":"J Nucl Med"},{"key":"7556_CR27","doi-asserted-by":"crossref","unstructured":"Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR et al. Novel framework for treatment response evaluation using PSMA-PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;jnumed.121.263072.","DOI":"10.2967\/jnumed.121.263072"},{"key":"7556_CR28","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2967\/jnumed.123.267234","volume":"65","author":"A Gafita","year":"2024","unstructured":"Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, et al. RECIP 1.0 predicts progression-free survival after [177 lu]lu-PSMA radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2024;65:917\u201322.","journal-title":"J Nucl Med"},{"key":"7556_CR29","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s12149-024-01954-0","volume":"38","author":"\u0130 Kaplan","year":"2024","unstructured":"Kaplan \u0130, K\u00f6mek H, Can C, Akdeniz N, G\u00fczel Y, Kepenek F, et al. Should new organ involvement be included in response evaluation criteria in PSMA imaging?? Ann Nucl Med. 2024;38:825\u201334.","journal-title":"Ann Nucl Med"},{"key":"7556_CR30","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00259-023-06536-2","volume":"51","author":"MC Neubauer","year":"2024","unstructured":"Neubauer MC, Nicolas GP, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, et al. Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. Eur J Nucl Med Mol Imaging. 2024;51:1185\u201393.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7556_CR31","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.3390\/cancers15133402","volume":"15","author":"A Hoffman","year":"2023","unstructured":"Hoffman A, Amiel GE. The impact of PSMA PET\/CT on modern prostate cancer management and decision making\u2014the urological perspective. Cancers. 2023;15:3402.","journal-title":"Cancers"},{"key":"7556_CR32","doi-asserted-by":"publisher","first-page":"8143","DOI":"10.7150\/thno.60222","volume":"11","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weckesser M, Kersting D, Seitzer KE, et al. Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy. Theranostics. 2021;11:8143\u201351.","journal-title":"Theranostics"},{"key":"7556_CR33","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222010","volume":"307","author":"R Seifert","year":"2023","unstructured":"Seifert R, Rasul S, Seitzer K, Eveslage M, Rahbar Nikoukar L, Kessel K, et al. A prognostic risk score for prostate cancer based on PSMA PET\u2013derived organ-specific tumor volumes. Radiology. 2023;307:e222010.","journal-title":"Radiology"},{"key":"7556_CR34","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2967\/jnumed.115.170167","volume":"57","author":"H Kulkarni","year":"2016","unstructured":"Kulkarni H, Singh A, Baum R. Response assessment to treatment with Lu-177 labeled PSMA inhibitor in patients with metastatic castration-resistant prostate cancer: differential response of bone versus lymph node lesions. J Nucl Med. 2016;57:1547\u20131547.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07556-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07556-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07556-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:24Z","timestamp":1769834604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07556-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7556"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07556-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective cohort study. Ethical approval for this study was obtained from Ankara Bilkent City Hospital\u2019s No: 2 Clinical Research Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All parents or persons having custody signed an informed consent for therapy, diagnostic procedures, and processing of patients\u2019 personal data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}